437 related articles for article (PubMed ID: 17689745)
1. Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus.
Pastromas S; Terzi AB; Tousoulis D; Koulouris S
Int J Cardiol; 2008 May; 126(1):3-12. PubMed ID: 17689745
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
3. Treatment of diabetic dyslipoproteinemia.
Steinmetz A
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):239-45. PubMed ID: 12951627
[TBL] [Abstract][Full Text] [Related]
4. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
5. Management of dyslipidemia in diabetes.
Solano MP; Goldberg RB
Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
[TBL] [Abstract][Full Text] [Related]
6. [Dyslipidemia in diabetes mellitus].
Niemeijer-Kanters SD; Banga JD; Erkelens DW
Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
[TBL] [Abstract][Full Text] [Related]
7. The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?
Kendall DM
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):27-48. PubMed ID: 15752920
[TBL] [Abstract][Full Text] [Related]
8. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.
O'Keefe JH; Bell DS
Am J Cardiol; 2007 Sep; 100(5):899-904. PubMed ID: 17719342
[TBL] [Abstract][Full Text] [Related]
9. Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.
Lewis GF
Can J Cardiol; 1995 May; 11 Suppl C():24C-28C. PubMed ID: 7750045
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and dyslipidemia.
Ginsberg HN; Tuck C
Heart Fail Monit; 2001; 2(1):14-20. PubMed ID: 12634894
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of dyslipidemia in type 2 diabetes.
Taskinen MR
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S180-8. PubMed ID: 11460569
[TBL] [Abstract][Full Text] [Related]
12. Postprandial lipoproteins in non-insulin-dependent diabetes mellitus.
Coppack SW
Diabet Med; 1997 Aug; 14 Suppl 3():S67-74. PubMed ID: 9272617
[TBL] [Abstract][Full Text] [Related]
13. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
15. [Postprandial hyperlipidemia, small and dense LDL, HDL sub-fractions].
Braschi S
Ann Med Interne (Paris); 2001 Apr; 152(3):162-8. PubMed ID: 11431575
[TBL] [Abstract][Full Text] [Related]
16. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
Reasner CA
J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
[TBL] [Abstract][Full Text] [Related]
17. Lipid abnormalities in insulin resistant states.
Watson KE; Horowitz BN; Matson G
Rev Cardiovasc Med; 2003; 4(4):228-36. PubMed ID: 14668690
[TBL] [Abstract][Full Text] [Related]
18. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
[TBL] [Abstract][Full Text] [Related]
19. Dyslipidemia in type 2 diabetes.
Krauss RM; Siri PW
Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of blood glucose levels in the pathogenesis of (atherosclerotic) macroangiopathy].
Simon K
Orv Hetil; 2004 Apr; 145(16):861-6. PubMed ID: 15156691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
